- Innocan Pharma Corporation (INNO) has announced the publication of an International Patent Application for a new particle-based formulation of CBD
- The patent application supports the potential for the company’s technology to deliver cannabinoids to the bloodstream
- Innocan Pharma is a pharmaceutical technology company
- InnoCan Pharma Corporation (INNO) opened trading at C$0.55 per share
Innocan Pharma Corporation (INNO) has announced the publication of an International Patent Application.
The patent application involves a new particle-based formulation of CBD, which allows a sustained release profile of CBD in plasma.
The publication of the patent application for Innocan’s CBD formulation platform provides additional protection with respect to the company’s intellectual property portfolio and is a milestone toward developing novel treatments for various ailments.
The patent application serves as a milestone in the research conducted in collaboration with the Hebrew University and supports the potential for the company’s technology to deliver cannabinoids to the bloodstream.
Innocan Pharma Ltd., a wholly-owned subsidiary of the company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem. The research and development initiative is led by Professor Chezy Barenholz, head of the Membrane and Liposome Research Department at The Hebrew University, which is the inventor of over fifty-five patent families, two of which underlie Doxil®, an FDA-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.
Innocan Pharma is a pharmaceutical technology company that focuses on the development of several drug delivery platforms containing CBD.
InnoCan Pharma Corporation (INNO) opened trading at C$0.55 per share.
